This study of national retail pharmacy data from 2013 to 2022, found an overall increase in buprenorphine dispensed to women of reproductive age and a marked increase in fills that were prescribed by nurse practitioners/physician assistants.
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 1 - 10 of 176. 10 per page. Page 1.
Advanced SearchASPE Issue Brief
Medicare Part D Enrollees Reaching the Out-of-Pocket Limit by June 2024
The Inflation Reduction Act established a limit on out-of-pocket spending (“the 2024 cap”) for enrollees with very high prescription drug spending in Medicare Part D, for the first time in the history of the program.
ASPE Issue Brief
Participant Diversity by Race, Ethnicity, and Sex in Rare Disease Clinical Trials: A Case Study of Eight Rare Cancers
Rare cancer clinical trials appear to enroll less diverse participants than clinical trials more broadly and therefore may require additional considerations or unique solutions to diversify participant recruitment. These differences persisted within both NIH and non-NIH funded trials.
Report
Impact of Climate Change on Health and Drug Demand
It is anticipated that extreme weather events due to climate change will increase the prevalence of a number of acute and chronic diseases. As a result, the demand for drugs to prevent or treat those conditions is likely to increase.
Report
Drug Development
The cost of bringing a medical product to the U.S. market has been increasing and clinical trials constitute a large portion of these costs. In drug development, the clinical phase lasts an average of around 95 months compared to 31 months for the non-clinical phase and accounts for 69 percent of overall R&D costs (DiMasi, et al., 2016).
ASPE Issue Brief
Opioid Use Treatment of Pregnant/Postpartum Women and their Children
This study represents findings from a descriptive analysis of a linked mother-child Medicaid claims dataset to examine the characteristics of pregnant women who use medication for opioid use disorder (MOUD) or intensive behavioral health treatment; additional analysis describes the mental health and neurodevelopment outcomes of their children at one year and three years.
Research Summary
FDA Breakthrough Therapy Designation Reduced Late-Stage Drug Development Time
This landing page presents the abstract of a paper published in Health Affairs. The full text of the article is available at: https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2023.00837.
ASPE Issue Brief
Medicare Drug Price Negotiation Program: Medicare Prices Negotiated for 2026 Compared to List and U.S. Market Prices
The Inflation Reduction Act (IRA) makes improvements to Medicare to increase accessibility and affordability of prescription drugs for Medicare enrollees, reduce the rate of growth in Medicare drug spending, and improve the financial sustainability of the Medicare program.
ASPE Issue Brief, Database, Dataset, Report
Developing a Database of SUD Treatment Needs
A 2020 study examined the feasibility of using substance use disorder (SUD) patient intake assessment data as source of information for treatment planning.
ASPE Data Point
Linking Medical Product Manufacturing Locations with Natural Hazard Risk: Implications for the Medical Product Supply Chain
This ASPE data point links manufacturer location data with the Federal Emergency Management Agency (FEMA) National Risk Index (NRI), which describes relative risk of experiencing a variety of natural hazards in order to highlight the ways in which natural disasters may pose supply chain vulnerabilities within the U.S.